{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:10:04Z","timestamp":1756289404097,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>Antiphospholipid antibody syndrome is an autoimmune condition with clinical manifestations of vascular thrombosis and adverse pregnancy outcomes including recurrent miscarriage, fetal loss, growth restriction and pre-eclampsia with persistent antiphospholipid antibodies on laboratory examination. Treatment is targeted at preventing recurrent thrombosis and improving pregnancy outcomes. Commonly, treatment includes aspirin and anticoagulation, however, newer immunomodulatory treatments may also improve outcomes. The case describes a patient with a history of multiple miscarriages and pregnancy losses, fetal growth restriction and pre-eclampsia, and pulmonary embolism. Because of her significant adverse pregnancy outcomes, she was treated with certolizumab with a successful delivery at 33 weeks and 6\u2009days. She also developed acute pancreatitis in the postpartum period. This is a rare condition, affecting 1\u201314\/10 000 births. The pancreatitis resolved with conservative management, and she had an uncomplicated interval cholecystectomy.<\/jats:p>","DOI":"10.1136\/bcr-2022-250664","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T22:45:18Z","timestamp":1716331518000},"page":"e250664","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Acute peripartum pancreatitis complicating seronegative antiphospholipid antibody syndrome in pregnancy"],"prefix":"10.1136","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct03152058","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03152058","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03152058","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Zoe","family":"Zimmer","sequence":"first","affiliation":[{"name":"Gynecologic Surgery and Obstetrics, Naval Medical Center San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Hill","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Fratto","sequence":"additional","affiliation":[{"name":"Maternal Fetal Medicine, Naval Medical Center San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica A","family":"Lutgendorf","sequence":"additional","affiliation":[{"name":"Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"2025082702483392000_17.5.e250664.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2025082702483392000_17.5.e250664.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170044"},{"key":"2025082702483392000_17.5.e250664.3","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310397082"},{"key":"2025082702483392000_17.5.e250664.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2003.12.006"},{"key":"2025082702483392000_17.5.e250664.5","unstructured":"FDA . Food and drug Administratino. CIMZIA: Certolizumab Pegol; 2017. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/1251602270lbl.pdf"},{"key":"2025082702483392000_17.5.e250664.6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2019.02.006","article-title":"Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: maternal-fetal outcomes in a series of 18 cases","volume":"49","author":"Alijotas-Reig","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2025082702483392000_17.5.e250664.7","unstructured":"National Library of Medicine (US . IMPACT study: improve pregnancy in APS with Certolizumab therapy [ClinicalTrials.gov]. Bethesda (MD); 2017. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03152058"},{"key":"2025082702483392000_17.5.e250664.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.485"},{"key":"2025082702483392000_17.5.e250664.9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320954520"},{"key":"2025082702483392000_17.5.e250664.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-522623"},{"key":"2025082702483392000_17.5.e250664.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.34402"},{"key":"2025082702483392000_17.5.e250664.12","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318787035"},{"key":"2025082702483392000_17.5.e250664.13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10067-018-4251-7","article-title":"Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements","volume":"38","author":"\u017digon","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025082702483392000_17.5.e250664.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes388"},{"key":"2025082702483392000_17.5.e250664.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.002"},{"key":"2025082702483392000_17.5.e250664.16","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-014-0485-9","article-title":"The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome","volume":"17","author":"Willis","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2025082702483392000_17.5.e250664.17","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/rheumatology\/kez419","article-title":"Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry","volume":"59","author":"Alijotas-Reig","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025082702483392000_17.5.e250664.18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12016-016-8569-0","article-title":"Pregnancy outcome in women with obstetric and thrombotic antiphospholipid syndrome \u2013 a retrospective analysis and a review of additional treatment in pregnancy","volume":"53","author":"Mayer-Pickel","year":"2017","journal-title":"Clinic Rev Allerg Immunol"},{"key":"2025082702483392000_17.5.e250664.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.012"},{"key":"2025082702483392000_17.5.e250664.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"2025082702483392000_17.5.e250664.21","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)90188-4"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-250664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:48:42Z","timestamp":1756288122000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-250664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,21]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bcr-2022-250664"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-250664","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}